Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology

Published: Jul 1, 2019
Abstract
Dopamine receptor D2 (DRD2) is a G protein-coupled receptor that is overexpressed and critical for survival in several cancers. ONC201, an imipridone small molecule, is a DRD2/3 antagonist in Phase II advanced cancer clinical trials with a compelling safety and efficacy profile. We evaluated the binding target, anti-tumor activity, biodistribution and safety of ONC206, a chemical derivative of ONC201 with the same imipridone core structure. GPCR...
Paper Details
Title
Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology
Published Date
Jul 1, 2019
Journal
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.